Payment overview · 2025
General Payments
$1,807.61
64 reported records · 13 companies
Healthcare provider profile · identity verified
Hua Ding
Allopathic & Osteopathic Physicians|Internal Medicine · FLUSHING, NY · NPI 1669545166
Verified facts
What the public records show
CMS Open Payments records show Hua Ding received $1,807.61 in general payments during 2025 across 64 reported records.
Gilead Sciences, Inc. accounted for 33.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Creon, Jardiance, Kerendia, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 789 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexium by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synjardy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $601.67 | 33.3% | 18 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $213.19 | 11.8% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $167.32 | 9.3% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $150.26 | 8.3% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $149.96 | 8.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $132.18 | 7.3% | 7 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $125.00 | 6.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $75.96 | 4.2% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $54.69 | 3.0% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $44.36 | 2.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.41 | 1.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.00 | 1.7% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $28.61 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,807.61 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $243.19 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $150.26 | 10 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $149.96 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $148.19 | 8 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $132.18 | 7 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $75.96 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $75.96 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $54.69 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $44.36 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $44.36 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.04 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $36.74 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $28.61 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $28.61 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 12 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 148 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 81 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 165 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 44 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 156 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
46 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
789 | 127 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
165 | 29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
36 | 15 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
158 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
148 | 147 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
156 | 107 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
165 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
233 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 4649 | 678 |
| Losartan Potassium | Losartan Potassium | 3903 | 529 |
| Amlodipine Besylate | Amlodipine Besylate | 3758 | 503 |
| Atorvastatin Calcium | Atorvastatin Calcium | 3344 | 464 |
| Metformin Hcl | Metformin Hcl | 1757 | 236 |
| Metoprolol Succinate | Metoprolol Succinate | 1600 | 240 |
| Simvastatin | Simvastatin | 1017 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 986 | 158 |
| Icosapent Ethyl | Icosapent Ethyl | 983 | 376 |
| Levothyroxine Sodium | Levothyroxine Sodium | 974 | 114 |
| Farxiga | Dapagliflozin Propanediol | 789 | 127 |
| Tamsulosin Hcl | Tamsulosin Hcl | 650 | 110 |
| Ammonium Lactate | Ammonium Lactate | 639 | 221 |
| Montelukast Sodium | Montelukast Sodium | 587 | 178 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 577 | 78 |
| Raloxifene Hcl | Raloxifene Hcl | 573 | 82 |
| Atenolol | Atenolol | 560 | 75 |
| Fluticasone Propionate | Fluticasone Propionate | 558 | 192 |
| Pioglitazone Hcl | Pioglitazone Hcl | 548 | 80 |
| Quetiapine Fumarate | Quetiapine Fumarate | 497 | 106 |
| Folic Acid | Folic Acid | 474 | 100 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 471 | 128 |
| Omeprazole | Omeprazole | 429 | 241 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 411 | 98 |
| Diclofenac Epolamine | Diclofenac Epolamine | 375 | 169 |
| Azithromycin | Azithromycin | 305 | 239 |
| Clopidogrel | Clopidogrel Bisulfate | 304 | 53 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 296 | 127 |
| Alendronate Sodium | Alendronate Sodium | 290 | 61 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 287 | 122 |
| Hydrochlorothiazide | Hydrochlorothiazide | 279 | 49 |
| Fenofibrate | Fenofibrate,micronized | 243 | 70 |
| Eliquis | Apixaban | 233 | 35 |
| Finasteride | Finasteride | 230 | 38 |
| Januvia | Sitagliptin Phosphate | 228 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 212 | 97 |
| Carvedilol | Carvedilol | 211 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 190 | 51 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 183 | 79 |
| Nitroglycerin | Nitroglycerin | 183 | 53 |
| Allopurinol | Allopurinol | 180 | 24 |
| Clobetasol Propionate | Clobetasol Propionate | 177 | 133 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 26 |
| Jardiance | Empagliflozin | 165 | 29 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 159 | 54 |
| Vemlidy | Tenofovir Alafenamide | 158 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 156 | 107 |
| Alcohol Pads | Alcohol Antiseptic Pads | 152 | 51 |
| Telmisartan | Telmisartan | 150 | 26 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 148 | 147 |
| Enalapril Maleate | Enalapril Maleate | 141 | 24 |
| Dapagliflozin | Dapagliflozin Propanediol | 139 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 137 | 76 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 136 | 28 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 134 | 25 |
| Xarelto | Rivaroxaban | 126 | 21 |
| Ursodiol | Ursodiol | 123 | 17 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 122 | 16 |
| Gabapentin | Gabapentin | 117 | 53 |
| Meclizine Hcl | Meclizine Hcl | 109 | 82 |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 108 | 20 |
| Sertraline Hcl | Sertraline Hcl | 105 | 21 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 102 | 18 |
| Valsartan | Valsartan | 100 | 14 |
| Azelastine Hcl | Azelastine Hcl | 97 | 43 |
| Tradjenta | Linagliptin | 95 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 93 | 19 |
| Celecoxib | Celecoxib | 87 | 72 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 85 | 45 |
| Hydrocortisone | Hydrocortisone | 84 | 33 |
| Paroxetine Hcl | Paroxetine Hcl | 83 | 17 |
| Creon | Lipase/Protease/Amylase | 81 | 17 |
| Gemfibrozil | Gemfibrozil | 78 | 22 |
| Donepezil Hcl | Donepezil Hcl | 77 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 77 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 75 | 68 |
| Procto-Med Hc | Hydrocortisone | 75 | 31 |
| Bepotastine Besilate | Bepotastine Besilate | 71 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 70 | suppressed |
| Famotidine | Famotidine | 69 | 38 |
| Entecavir | Entecavir | 67 | suppressed |
| Glipizide | Glipizide | 62 | 13 |
| Ezetimibe | Ezetimibe | 59 | 13 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 59 | 14 |
| Ranolazine Er | Ranolazine | 59 | suppressed |
| Glipizide Er | Glipizide | 56 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 55 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 54 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 35 |
| Amoxicillin | Amoxicillin | 47 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 45 |
| Prolia | Denosumab | 46 | 31 |
| Methimazole | Methimazole | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 41 |
| Kerendia | Finerenone | 44 | 13 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 43 | 34 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 43 | 14 |
| Econazole Nitrate | Econazole Nitrate | 43 | 18 |
| Mupirocin | Mupirocin | 43 | 38 |
| Mupirocin | Mupirocin Calcium | 42 | 35 |
| Glimepiride | Glimepiride | 41 | suppressed |
| Lisinopril | Lisinopril | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Multaq | Dronedarone Hcl | 36 | 11 |
| Synjardy | Empagliflozin/Metformin Hcl | 36 | 15 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Furosemide | Furosemide | 31 | suppressed |
| Meloxicam | Meloxicam | 30 | 28 |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Lactulose | Lactulose | 26 | 11 |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 24 | 14 |
| Proctozone-Hc | Hydrocortisone | 24 | 13 |
| Ciclopirox | Ciclopirox | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | 12 |
| Cephalexin | Cephalexin | 21 | 19 |
| Dilt-Xr | Diltiazem Hcl | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 19 |
| Colchicine | Colchicine | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 17 | 12 |
| Acyclovir | Acyclovir | 16 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | 13 |
| Ketoconazole | Ketoconazole | 16 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Prednisone | Prednisone | 15 | 14 |
| Cilostazol | Cilostazol | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Brilinta | Ticagrelor | 13 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 12 | 12 |
| Alogliptin | Alogliptin Benzoate | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 12 | 12 |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,807.61 · 64 records | Gilead Sciences, Inc. | ABRYSVO, AIRSUPRA, AREXVY, CAPVAXIVE, COMIRNATY, CREON, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GARDASIL 9, INGREZZA, JARDIANCE, Kerendia, LINZESS, NEXLETOL, PREVNAR 20, SHINGRIX, TRELEGY ELLIPTA | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error